BioSpace News Archive

Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced that Dr. Robert.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the formation of its Executive Scientific Advisory Board, chaired by Dr. Carl Regillo M.D., FACS, Chief of the Retina Service at Wills Eye Hospital.

FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, announced the publication of results from its Phase 2 human challenge study of Bris2007 M2SR, the Company’s investigational, supra-seasonal, live, single-replication, intranasal influenza vaccine.

Amicus Therapeutics, a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, announced the European Commission has approved Galafold® for use in adolescents aged 12 to <16 years weighing ≥ 45 kg with a confirmed diagnosis of Fabry disease and who have an amenable mutation.

OKYO Pharma Limited is pleased to announce its final audited results for the year ended 31 March 2021.

Addex Therapeutics Ltd, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.

Mainz, Germany, August 2, 2021 – BioNTech SE will announce its financial results for the second quarter on Monday, August 9th, 2021.

TG Therapeutics, Inc. announced its financial results for the second quarter ending June 30, 2021 and recent company developments, along with a business outlook for the remainder 2021.

Autolus Therapeutics plc announced an agreement with Moderna, a biotechnology company pioneering messenger RNA therapeutics and vaccines, granting Moderna an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus’ proprietary binders for up to four immuno-oncology targets.

Ipsen and Exicure Inc. have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids as potential investigational treatments for Huntington’s disease and Angelman syndrome.